Recent Company News

• 02:59 PM ET Aug 10, 2026
  

  Eli Lilly widens lead in obesity drug market after Novo sales outlook failed in impress in GLP-1 themes (10-Aug)

• 01:49 PM ET Aug 07, 2026
  

  Street Takeaways - GLP-1 Rx Tracker for week ended July 31st; Foundayo TRx ~+16.4% w/w; Oral Wegovy TRx +0.6% w/w

• 04:15 PM ET Aug 06, 2026
  

  Structure Therapeutics reports Q2 net income ($106.2M) vs FactSet ($80.7M) [11 est, ($99.5)-(43M)] ($52.62, 0.00)

• 11:08 AM ET Jun 17, 2026
  

  Johnson & Johnson CEO says focus remains on cancer, not obesity drugs - Bloomberg ($233.61, -1.57)

• 11:37 AM ET Jun 10, 2026
  

  StreetAccount ESG Research Round Up

• 10:47 AM ET Jun 09, 2026
  

  Transcript Intelligence: Structure Therapeutics at Goldman Sachs Global Healthcare Conference ($39.86, +2.08)

• 09:32 AM ET Jun 09, 2026
  

  Premarket themes include continued AI hardware rebound (9-Jun)

• 09:17 AM ET Jun 09, 2026
  

  StreetAccount Summary - US Pre-market trading update

• 08:17 AM ET Jun 09, 2026
  

  StreetAccount Summary - US Pre-market trading

• 04:08 PM ET Jun 05, 2026
  

  Structure Therapeutics announces publication in Nature Medicine highlighting phase 2B ACCESS program of Aleniglipron for obesity ($37.58, 0.00)